Plinsinga Melanie, Singh Ben, Bloomquist Kira, Bernas Michael, Geyer Debbie, Devoogdt Nele, Koelmeyer Louise, Piller Neil, Reul-Hirche Hildegard, Rockson Stanley, Hayes Sandi
School of Health Sciences and Social Work, Griffith University, Brisbane, Queensland, Australia
University of South Australia, Adelaide, South Australia, Australia.
BMJ Open. 2024 Dec 20;14(12):e086293. doi: 10.1136/bmjopen-2024-086293.
Given the projected rise in the incidence of cancer treatment-related conditions, such as lymphoedema, and the limited research on lymphoedema in cancers with poor prognoses, there is a need for a better understanding of cancer-related lymphoedema incidence and associated risk factors across all types of cancers. The objectives of this review are (1) to produce a resource on an open-access platform that facilitates continuous update of incidence estimates and risk factors as evidence emerges, (2) to provide the most up-to-date estimate of the incidence of cancer-related lymphoedema and (3) to evaluate the strength and consistency of the association between lymphoedema and cancer treatment and non-treatment-related risk factors.
A living systematic and grey literature search will be conducted to identify studies reporting the incidence, prevalence of lymphoedema or associated risk factors in individuals who have undergone treatment for any type of cancer. Two investigators will independently extract data and assess the risk of bias using the Cochrane Risk of Bias Tool Version 2.0, the Risk of Bias in Non-randomised Studies - of Interventions or the National Institutes of Health Heart, Lung and Blood Institute Study Quality Assessment Tools, depending on study design. The overall strength of evidence will be appraised with the Grading of Recommendations, Assessment, Development and Evaluations tool. Random effect models will be used to produce pooled overall lymphoedema incidence estimates. Subgroup analyses that explore relationships between lymphoedema incidence and lymphoedema measurement method, time since cancer diagnosis and treatment and diagnosis, treatment and behavioural characteristics will be conducted dependent on available data.
This living systematic review enables clinicians and researchers to consult a contemporary, comprehensive overview of the incidence of cancer-related lymphoedema and the association between lymphoedema and treatment and non-treatment-related risk factors.
CRD42022333291.
鉴于预计与癌症治疗相关病症(如淋巴水肿)的发病率将会上升,且针对预后不良癌症患者的淋巴水肿研究有限,因此有必要更好地了解各类癌症中与癌症相关的淋巴水肿发病率及相关风险因素。本综述的目的是:(1)在开放获取平台上创建一个资源库,以便随着证据的出现,促进对发病率估计和风险因素的持续更新;(2)提供与癌症相关淋巴水肿发病率的最新估计;(3)评估淋巴水肿与癌症治疗及非治疗相关风险因素之间关联的强度和一致性。
将进行一项动态系统综述和灰色文献检索,以识别报告接受过任何类型癌症治疗的个体中淋巴水肿发病率、患病率或相关风险因素的研究。两名研究人员将根据研究设计,分别使用Cochrane偏倚风险工具2.0版、非随机干预研究中的偏倚风险工具或美国国立卫生研究院心肺血液研究所研究质量评估工具独立提取数据并评估偏倚风险。将使用推荐分级、评估、制定与评价工具对证据的总体强度进行评估。将使用随机效应模型得出合并的总体淋巴水肿发病率估计值。将根据现有数据进行亚组分析,探讨淋巴水肿发病率与淋巴水肿测量方法、癌症诊断和治疗后的时间以及诊断、治疗和行为特征之间的关系。
这项动态系统综述使临床医生和研究人员能够查阅有关与癌症相关淋巴水肿发病率以及淋巴水肿与治疗及非治疗相关风险因素之间关联的当代综合概述。
PROSPERO注册号:CRD42022333291。